PNU 142633F

Drug Profile

PNU 142633F

Alternative Names: PNU 142633

Latest Information Update: 12 Aug 2008

Price : $50

At a glance

  • Originator Pfizer
  • Class Non-opioid analgesics; Piperidines; Small molecules
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cluster headache; Headache; Migraine

Most Recent Events

  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 15 Jan 2003 Phase-II clinical trials in Headache in USA (PO)
  • 15 Jan 2003 Phase-II clinical trials in Migraine in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top